Acurx Pharmaceuticals
ACXP
3 hedge funds and large institutions have $163K invested in Acurx Pharmaceuticals in 2021 Q2 according to their latest regulatory filings, with 3 funds opening new positions, increasing their positions, reducing their positions, and closing their positions.
0.01% more ownership
Funds ownership: 0% → 0.01% (+0.01%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PCM
Parsons Capital Management
Providence,
Rhode Island
|
+$100K |
| 2 |
TAM
Tocqueville Asset Management
New York
|
+$66.9K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
+$3.08K |
Top Sellers
ACXP Hedge Fund Activity: Q2 2021 in Review
3 of the 5,745 institutional investors tracked by Wall St. Rank reported a position in Acurx Pharmaceuticals (ACXP) for Q2 2021, worth a combined $163K.
Buyers outnumbered sellers: 3 funds opened new ACXP positions and 0 closed out — a net gain of 3 holders — while 0 added to existing stakes and 0 trimmed.
The largest buyer was Parsons Capital Management, opening a new position worth an estimated $100K.
- 3 institutional investors held Acurx Pharmaceuticals (ACXP) as of Q2 2021, up from 0 in Q1 2021.
- Funds reported $163K of Acurx Pharmaceuticals stock for Q2 2021.
- 3 funds opened new Acurx Pharmaceuticals positions in Q2 2021 and 0 closed out, a net change of +3 holders.
- The largest Acurx Pharmaceuticals buyer in Q2 2021 was Parsons Capital Management, an estimated $100K added.
Based on aggregated 13F filings for Q2 2021.